Skip to content

A Comparative Study of Fusional Vergence According to Ocular Dominance in Healthy Subjects

A Comparative Study of Fusional Vergence According to Ocular Dominance in Healthy Subjects

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07697131
Acronym
ECAFOSS
Enrollment
60
Registered
2026-07-13
Start date
2026-08-20
Completion date
2027-06-01
Last updated
2026-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No Eye Disorder

Keywords

Fusional vergence, Ocular dominance, Orthoptic practice

Brief summary

In orthoptics, fusional vergence (FV) measurement is one of the key tests used to assess fusion ability. These amplitudes are generally reduced in individuals with convergence insufficiency. Fusional vergence are quantified by placing a prism bar randomly in front of one eye-first for distance vision and then for near vision. Rehabilitation exercises using the prism bar are also performed in the same manner. Depending on orthoptic practice, the prism bar is placed in front of the left eye or the right eye, in a dogmatic manner, or in front of the right eye, in a conventional manner, without any study providing any justification. However, some practitioners report interocular differences when measuring fusion amplitudes depending on which eye is prismed, while others do not. The hypothesis put forward is that, in individuals with an interocular difference in fusional vergence, ocular dominance (sensory and motor) could be the cause of this measurement discrepancy. The objective is therefore to compare the difference in fusional vergence depending on whether the dominant or non-dominant eye is tested, using a randomized order of eyes and tests. If this hypothesis is confirmed (greater fusional vergence when tested on the dominant eye), this would: (1) enhance our understanding of fusion mechanisms, (2) provide more targeted insights for the assessment, quantification, and rehabilitation of fusional vergence to improve the effectiveness of orthoptic intervention.

Detailed description

In orthoptics, fusional vergence (FV) measurement is one of the key tests used to assess fusion ability. These amplitudes are generally reduced in individuals with convergence insufficiency. Fusional vergence are quantified by placing a prism bar randomly in front of one eye-first for distance vision and then for near vision. Rehabilitation exercises using the prism bar are also performed in the same manner. Depending on orthoptic practice, the prism bar is placed in front of the left eye or the right eye, in a dogmatic manner, or in front of the right eye, in a conventional manner, without any study providing any justification. However, some practitioners report interocular differences when measuring fusion amplitudes depending on which eye is prismed, while others do not. The hypothesis put forward is that, in individuals with an interocular difference in fusional vergence, ocular dominance (sensory and motor) could be the cause of this measurement discrepancy. The objective is therefore to compare the difference in fusional vergence depending on whether the dominant or non-dominant eye is tested, using a randomized order of eyes and tests. If this hypothesis is confirmed (greater fusional vergence when tested on the dominant eye), this would: (1) enhance our understanding of fusion mechanisms, (2) provide more targeted insights for the assessment, quantification, and rehabilitation of fusional vergence to improve the effectiveness of orthoptic intervention. The study consists of one-hour eye examinations of healthy individuals with no visual or oculomotor disorders.

Interventions

OTHERFusional Vergence assessment

Measurement of sensorimotor fusional vergence in the right and left eyes, in divergence and convergence, first for distance vision and then for near vision. A random draw will determine which eye is tested first for distance vision, followed by a second draw for near vision, in order to minimize training bias. Prior to this, a stereoscopic acuity test will be performed to confirm the presence of binocular vision.

OTHEROcular dominance evaluation

Assessment of ocular dominance for: * The dominant eye using the monocular blurriness test and the red-glass test * The leading eye using the Mawas plate Punctum Proximum convergence test and the bilateral prismatic test for oculomotor dominance * The preferred eye using the spontaneous ocular method * The target eye using the Hole-in-Card method: hole-in-card test

OTHERComplete Orthoptic

Conducting an orthoptic evaluation to verify that patients meet the study's inclusion criteria: * assessment of visual acuity and refraction * assessment of stereoscopic vision * cover-test to screen potential abnormal phorias * measurement of interpupillary distance

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults between the ages of 18 and 35 with no known eye conditions, with or without ametropia. If ametropia is present: it must be corrected * Subjects with no history of eye surgery, including refractive surgery * Subjects who have been informed about the study and have freely and knowingly consented to participate in the study and to the collection of data

Exclusion criteria

* Subjects with strabismus * Subjects with visual acuity of less than 20/20; or anisometropia

Design outcomes

Primary

MeasureTime frameDescription
Amplitude of fusional vergenceDay 0Values of horizontal fusional vergence measured using a horizontal Berens prism bar in divergence and convergence, for distance and near vision, in the right eye and the left eye and reported in prism diopters.
Laterality ocular dominanceDay 0Assessment of ocular dominance for: * The dominant eye using the monocular blur test and the red-glass test * The leading eye using the Punctum Proximum of Convergence (PPC) test with the Mawas plate and bilateral prism test for oculomotor dominance * The preferred eye using the spontaneous ocular method * The target eye using the Hole-in-Card method: hole-in-card test All tests classify the ocular dominance into 3 categories : Left, Right, None.
Lateralization quotient value (LQ)Day 0Determination of the lateralization quotient value by the mean of previous responses of the ocular dominance tests.

Secondary

MeasureTime frameDescription
Assessment of the degree of agreement among the various tests for ocular dominanceDay 0Compilation of responses to ocular dominance tests (sensorial and motor dominant eye, target eye and preferred eye) and lateralization quotient.
Agreeement between the bilateral prismatic test (new test for oculomotor dominance laterality determination and standard ocular dominance testsDay 0Evaluation of a new test (bilateral prismatic test for oculomotor dominance) and comparison to usually ocular dominance test. All tests classify the ocular dominance into 3 categories : Left, Right, None. This part tends to evaluation the efficacity and the utility of a new test for ocular dominance.
Assessment of the difference in fusional vergence measurements between the right and left eyes and the laterality quotientDay 0Assessment of the difference in fusional vergence measurements between the right and left eyes and the laterality quotient.
Correlation between inter-pupillary distance measurements and differences in fusion amplitude measurements between the right and left eyesDay 0Measurements of interpupillary distance and overall fusion ability, for distance vision and near vision.

Countries

France

Contacts

CONTACTMaxence Rateaux, PhD
maxence.rateaux@aphp.fr01 44 49 53 62
CONTACTHélène Morel
helene.morel@aphp.fr01 44 38 16 53
PRINCIPAL_INVESTIGATORMaxence Rateaux, PhD

Assistance Publique - Hôpitaux de Paris

STUDY_DIRECTORDominique MD, PhD BREMOND-GIGNAC

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 27, 2026